TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00719095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine taper followed by naltrexone maintenance
Description: direct comparison of 1-, 2- and 4-week durations of buprenorphine taper for treating prescription opioid abusers; those who successfully taper without resumption of illicit opioid use are subsequently transitioned to oral naltrexone therapy for the remainder of the 12-week trial; all participants receive a platform of intensive individual behavioral therapy and on-site urinalysis monitoring throughout the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine taper followed by naltrexone maintenance
Description: direct comparison of 1-, 2- and 4-week durations of buprenorphine taper for treating prescription opioid abusers; those who successfully taper without resumption of illicit opioid use are subsequently transitioned to oral naltrexone therapy for the remainder of the 12-week trial; all participants receive a platform of intensive individual behavioral therapy and on-site urinalysis monitoring throughout the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine taper followed by naltrexone maintenance
Description: direct comparison of 1-, 2- and 4-week durations of buprenorphine taper for treating prescription opioid abusers; those who successfully taper without resumption of illicit opioid use are subsequently transitioned to oral naltrexone therapy for the remainder of the 12-week trial; all participants receive a platform of intensive individual behavioral therapy and on-site urinalysis monitoring throughout the trial

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Study: NCT04560790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD111 Adult single group Dose
Description: 3-6 Participants will receive a single group dose administered via corneal injection in the study eye.
Study: NCT01464944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Paracetamol, and 2 Placebo tablets of Acetylsalicylic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Paracetamol, orally, single dose
Study: NCT02462629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLZ-100
Study: NCT01877278

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wearable pulsed electromagnetic fields
Study: NCT00759200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alb-interferon alfa 2b
Description: 900 mcg every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alb-interferon alfa 2b
Description: 1200 mcg every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alb-interferon alfa 2b
Description: 1500 mcg every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alb-interferon alfa 2b
Description: 1800 mcg every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peg-interferon
Description: Peg-interferon alfa 2a: 180 mcg 1x per wk.
Study: NCT04332276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-dopamine
Description: During the phase 1 (titration), it is planned to increase dopamine by maximum 0.25 mg per hour over the daytime period, which corresponds to a maximum increase of 4.5 mg per day (based on the 18 hours of the daytime period, since nocturnal needs are much less important).~Then, depending on tolerance and efficacy, conservative titration will be continued for a target dose of 30-87 mg per day.~During the phase 2 (efficacy), the treatment will be maintained at the minimum effective dose, planned between 30 and 87 mg per day, for 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: optimized oral treatment
Description: The patient will received his usual dopaminergic treatment.
Study: NCT01877278

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wearable pulsed electromagnetic fields
Study: NCT00674063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alefacept
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alefacept
Description: IV
Study: NCT00771316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0826 (ertapenem)
Description: A single dose of 1.0g IV infused over a 30 minute interval at hour 0
Study: NCT01157598

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bispectral index monitoring
Description: parameter monitoring of bispectral index

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: bispectral index monitoring
Description: parameter monitoring of bispectral index
Study: NCT05586386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cherry group
Description: 200 mL of DSC juice twice/day supplemented with 3g of DSC powder twice/day for 30 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo group
Description: 200 mL of placebo juice twice/day
Study: NCT05701124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab (0.25 mg/0.025 mL)
Description: Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant. The intraocular pressure and central artery perfusion were then checked.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab (0.25 mg/0.025 mL)
Description: Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant. The intraocular pressure and central artery perfusion were then checked.
Study: NCT03675893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole is a hormonal therapy that works by lowering the production of estrogen in the body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole is a hormonal therapy that works by lowering the production of estrogen in the body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole is a hormonal therapy that works by lowering the production of estrogen in the body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole is a hormonal therapy that works by lowering the production of estrogen in the body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole is a hormonal therapy that works by lowering the production of estrogen in the body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor.
Study: NCT00771316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: meropenem
Description: 500 mg IV infused over a 30 minute interval at hours 0, 8, and 16 for at least 4 days
Study: NCT00602667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Chemotherapy
Description: All patients will receive 4 identical cycles of induction chemotherapy including highdose (5 g/m2 or 2.5g/m2 for patients less than or equal to 31 days of age at enrollment) intravenous methotrexate and standard dose vincristine, cisplatin, and cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Chemotherapy
Description: All patients will receive 4 identical cycles of induction chemotherapy including highdose (5 g/m2 or 2.5g/m2 for patients less than or equal to 31 days of age at enrollment) intravenous methotrexate and standard dose vincristine, cisplatin, and cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Chemotherapy
Description: All patients will receive 4 identical cycles of induction chemotherapy including highdose (5 g/m2 or 2.5g/m2 for patients less than or equal to 31 days of age at enrollment) intravenous methotrexate and standard dose vincristine, cisplatin, and cyclophosphamide.
Study: NCT00842803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin infusion (25% albumin)
Description: Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
Study: NCT04351672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Time-Restricted Feeding
Description: Eat between 8 am and 4 pm for two weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late Time-Restricted Feeding
Description: Eat between 1 pm and 9 pm for two weeks
Study: NCT03378635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: Glucagon analog

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GlucaGen
Description: Native glucagon
Study: NCT00602667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Risk Therapy
Description: Induction will be followed by further conventional chemotherapy with carboplatin, cyclophosphamide, and etoposide. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
Study: NCT03378635

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for dasiglucagon
Study: NCT00602667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Risk Therapy
Description: High risk patients will also receive vinblastine with each course of induction chemotherapy. Induction will be followed by either chemotherapy with targeted intravenous topotecan and cyclophosphamide or optional craniospinal irradiation (CSI). CSI will be offered only to patients who reach 3 years of age by the end of induction only. After consolidation, all patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
Study: NCT02301793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse education in contemporary format
Description: Education about VTE was delivered through a web-based contemporary interactive format

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse education in traditional format
Description: Education about VTE was delivered through a web-based traditional linear Powerpoint format with voice over.
Study: NCT00602667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermediate-Risk Therapy
Description: Induction will be followed by consolidation focal radiotherapy (RT) to the tumor bed. Patients less than 12 months old upon completion of induction will receive low risk chemotherapy to delay RT until the age of 12 months. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).~Note: The option to receive focal proton beam irradiation was suspended 10/29/2015. Focal photon beam irradiation continues as part of the treatment plan.
Study: NCT03118973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goff trans-pancreatic septotomy vs. Double wire technique
Description: Goff trans-pancreatic septotomy vs. Double wire technique for achieving biliary access when biliary cannulation is challenging.
Study: NCT00648713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine Hydrochloride Tablets 250 mg
Description: 250mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamisil® Tablets 250 mg
Description: 250mg, single dose fed
Study: NCT01292993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg LX4211
Description: 400 mg of LX4211 given as a solid oral dose form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg LX4211
Description: 400 mg of LX4211 given as a solid oral dose form
Study: NCT03109054

Intervention type: DIAGNOSTIC_TEST
Intervention: State-Trait Anxiety Inventory Test
Description: All patients will take a State-Trait Anxiety Inventory Test. After the test patients will enroll low or high anxiety level.
Study: NCT01292993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000 mg metformin
Description: 1000 mg metformin given as a solid oral dose form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000 mg metformin
Description: 1000 mg metformin given as a solid oral dose form
Study: NCT04052282

Intervention type: DEVICE
Intervention: Mobile Health App
Description: There is no intervention
Study: NCT04195256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN Ketodex (D4K2)
Description: Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 4 mcg/kg (0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 2 mg/kg (0.04 mL/kg) of 50 mg/mL solution, maximum of 200 mg (4 mL) (D4K2), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN Ketodex (D3K3)
Description: Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 3 mcg/kg (0.03 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 3 mg/kg (0.06 mL/kg) of 50 mg/mL solution, maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN Ketodex (D2K4)
Description: Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 2 mcg/kg (0.02 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 4 mg/kg (0.08 mL/kg) of 50 mg/mL solution, maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Ketamine
Description: Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 100 mg (2 mL) AND two aliquots of 0.9% normal saline in 3 possible combinations: (i) 0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo D4K2), (ii) 0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) (placebo D3K3), (iii) 0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo D2K4), delivered intranasally using a MAD and divided to both nares
Study: NCT04279067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI-FES dorsiflexion therapy
Description: BCI technology enables direct brain control of external devices such as assistive devices and prostheses by translating brain waves into control signals. When BCI systems are integrated with functional electrical stimulation (FES) systems, they can be used to deliver a novel physical therapy to improve movement after stroke. The automated software will analyze the data to generate and calibrate a BCI decoder. In the online phase, the subjects will perform 20-25 BCI-FES runs. In each run, subjects will follow 10 alternating epochs of 10-s long idling/dorsiflexion textual cues, and respond by either idling or attempting dorsiflexion to elicit BCI-FES mediated contractions of the TA muscle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy one hour
Description: This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy two hours
Description: This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
Study: NCT00945997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: mifepristone 200 mg followed by 200 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: mifepristone 200 mg followed by 400 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
Study: NCT03171051

Intervention type: DEVICE
Group type: OTHER
Intervention: 950 nm LED Device
Description: Device to be used in aesthetic and cosmetic procedures which consists of a console and an applicator belt that delivers the treatment LED to the subject's skin.

Intervention type: DEVICE
Group type: OTHER
Intervention: 1050nm Diode Laser Device
Description: FDA approved laser device that has been shown to reduce fat in the flanks by heating the fat cells and causing them to burst. The contents of the cells are then cleared naturally by the body.
Study: NCT03885440

Intervention type: OTHER
Intervention: Age
Description: Age\<40 years old is chosen as the cutoff value.

Intervention type: OTHER
Intervention: Age
Description: Age\<40 years old is chosen as the cutoff value.

Intervention type: OTHER
Intervention: OSA
Description: The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.

Intervention type: OTHER
Intervention: OSA
Description: The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
Study: NCT00445978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin Dihydrochloride
Description: Subjects will receive oral, once-daily (for 2.5, 5, 10mg/kg/day doses) or twice-daily (for the 20 mg/kg/day dose) sapropterin dihydrochloride during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks as follows: 2.5, 5, 10, and 20 mg/kg/day. Dosing was with 100 mg tablets and rounded to the nearest whole tablet. Each dose was taken within 1 hour after the morning meal. Subjects may continue in an optional extension phase at the highest tolerated dose for up to a total of 2 years.
Study: NCT02378623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
Study: NCT02245178

Intervention type: PROCEDURE
Intervention: Lung spirometry
Description: measurement of pulmonary function pre- and post-bronchodilator

Intervention type: OTHER
Intervention: CT scan analysis
Description: Analysis of existing year 25 thoracic CT scans for lung and intrathoracic vascular structure
Study: NCT00972088

Intervention type: DEVICE
Group type: OTHER
Intervention: capsule endoscopy
Description: The disposable, ingestible PillCam® SB2 Capsule acquires the video images during natural propulsion through the digestive system. The Capsule transmits the acquired images via digital radio frequency communication channel to the Given® Data Recorder unit located outside the body.
Study: NCT03194529

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: Fecal Microbiota Transplantation, single dose, 50g of stool, delivered via standard of care upper endoscopy into jejunum.
Study: NCT00027300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab 300 mg IV infusion, every 4 weeks, for up to 116 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, IV infusion, every 4 weeks, for up to 116 weeks.